Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · April 15, 2024

Outcomes of Tucatinib Combination Treatment After Trastuzumab Deruxtecan Therapy in Patients With ERBB2-Positive Metastatic Breast Cancer

JAMA Network Open


Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Network Open
Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer
JAMA Netw Open 2024 Apr 01;7(4)e244435, JS Frenel, J Zeghondy, C Guérin-Charbonnel, A Mailliez, E Volant, F Poumeaud, A Patsouris, M Arnedos, C Bailleux, J Cabal, L Galland, A de Nonneville, S Guiu, F Dalenc, B Pistilli, T Bachelot, JY Pierga, F Le Du, F Bocquet, L Larrouquere, D Loirat

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading